Current genomic predictors of resistance to induction chemotherapy in AML include mutations in RUNX1, ASXL1, and TP53; elevated SNP-A–based genomic complexity; and specific recurrent copy number aberrations/loss of heterozygosity (32). This evidence concerns the gene TP53 and acute myeloid leukemia.